Impact of rituximab on COVID-19 outcomes

Rituximab is associated with prolonged B-cell depletion and secondary hypogammaglobulinemia and is associated with a dampened humoral response and increased infectious complications. To describe the potential impact of prior rituximab therapy on clinical outcomes from SARS-CoV-2 infection and develo...

Descripción completa

Detalles Bibliográficos
Autores principales: Levavi, Hannah, Lancman, Guido, Gabrilove, Janice
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8455155/
https://www.ncbi.nlm.nih.gov/pubmed/34549309
http://dx.doi.org/10.1007/s00277-021-04662-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8455155/
https://www.ncbi.nlm.nih.gov/pubmed/34549309
http://dx.doi.org/10.1007/s00277-021-04662-1

Ejemplares similares